Lymphoma, Large B-Cell, Diffuse
"Lymphoma, Large B-Cell, Diffuse" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.
| Descriptor ID |
D016403
|
| MeSH Number(s) |
C04.557.386.480.150.585 C15.604.515.569.480.150.585 C20.683.515.761.480.150.585
|
| Concept/Terms |
Lymphoma, Large B-Cell, Diffuse- Lymphoma, Large B-Cell, Diffuse
- Diffuse, Large B-Cell, Lymphoma
- Histiocytic Lymphoma
- Histiocytic Lymphomas
- Lymphomas, Histiocytic
- Histiocytic Lymphoma, Diffuse
- Diffuse Histiocytic Lymphoma
- Diffuse Histiocytic Lymphomas
- Histiocytic Lymphomas, Diffuse
- Lymphoma, Diffuse Histiocytic
- Lymphomas, Diffuse Histiocytic
- Large Lymphoid Lymphoma, Diffuse
- Lymphoma, Large-Cell, Diffuse
- Lymphoma, Diffuse Large-Cell
- Lymphoma, Diffuse Large Cell
- Lymphoma, Histiocytic
- Lymphoma, Large Lymphoid, Diffuse
- Lymphoma, Histiocytic, Diffuse
- Lymphoma, Large Cell, Diffuse
- Diffuse Large-Cell Lymphoma
- Diffuse Large Cell Lymphoma
- Diffuse Large-Cell Lymphomas
- Large-Cell Lymphomas, Diffuse
- Lymphomas, Diffuse Large-Cell
- Large-Cell Lymphoma, Diffuse
- Large Cell Lymphoma, Diffuse
|
Below are MeSH descriptors whose meaning is more general than "Lymphoma, Large B-Cell, Diffuse".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Lymphoma [C04.557.386]
- Lymphoma, Non-Hodgkin [C04.557.386.480]
- Lymphoma, B-Cell [C04.557.386.480.150]
- Lymphoma, Large B-Cell, Diffuse [C04.557.386.480.150.585]
- Hemic and Lymphatic Diseases [C15]
- Lymphatic Diseases [C15.604]
- Lymphoproliferative Disorders [C15.604.515]
- Lymphoma [C15.604.515.569]
- Lymphoma, Non-Hodgkin [C15.604.515.569.480]
- Lymphoma, B-Cell [C15.604.515.569.480.150]
- Lymphoma, Large B-Cell, Diffuse [C15.604.515.569.480.150.585]
- Immune System Diseases [C20]
- Immunoproliferative Disorders [C20.683]
- Lymphoproliferative Disorders [C20.683.515]
- Lymphoma [C20.683.515.761]
- Lymphoma, Non-Hodgkin [C20.683.515.761.480]
- Lymphoma, B-Cell [C20.683.515.761.480.150]
- Lymphoma, Large B-Cell, Diffuse [C20.683.515.761.480.150.585]
Below are MeSH descriptors whose meaning is more specific than "Lymphoma, Large B-Cell, Diffuse".
This graph shows the total number of publications written about "Lymphoma, Large B-Cell, Diffuse" by people in this website by year, and whether "Lymphoma, Large B-Cell, Diffuse" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 |
| 1997 | 2 | 0 | 2 |
| 1998 | 1 | 0 | 1 |
| 2002 | 3 | 1 | 4 |
| 2003 | 2 | 0 | 2 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 3 | 0 | 3 |
| 2008 | 1 | 0 | 1 |
| 2009 | 3 | 0 | 3 |
| 2010 | 3 | 0 | 3 |
| 2011 | 6 | 1 | 7 |
| 2012 | 3 | 0 | 3 |
| 2013 | 5 | 0 | 5 |
| 2014 | 6 | 0 | 6 |
| 2015 | 6 | 2 | 8 |
| 2016 | 8 | 1 | 9 |
| 2017 | 5 | 1 | 6 |
| 2018 | 3 | 0 | 3 |
| 2019 | 4 | 0 | 4 |
| 2020 | 8 | 0 | 8 |
| 2021 | 5 | 1 | 6 |
| 2022 | 10 | 0 | 10 |
| 2023 | 6 | 0 | 6 |
| 2024 | 5 | 3 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lymphoma, Large B-Cell, Diffuse" by people in Profiles.
-
Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centers. Haematologica. 2025 Mar 01; 110(3):706-714.
-
Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B-Cell Lymphoma. Am J Hematol. 2025 Feb; 100(2):236-248.
-
EBV and post-transplant lymphoproliferative disorder: a complex relationship. Hematology Am Soc Hematol Educ Program. 2024 12 06; 2024(1):728-735.
-
Hepatitis E virus infection after CAR T-cell treatment: An important complication in patients already facing significant health challenges. Br J Haematol. 2025 Mar; 206(3):1020-1021.
-
Real-world data on the clinical features, therapy patterns, and outcomes of older adults with diffuse large B-cell lymphoma in Latin America: A study from the Grupo de Estudio Latinoamericano de Linfoproliferativos (GELL). J Geriatr Oncol. 2025 Jan; 16(1):102160.
-
High-grade B-cell lymphomas: Double hit and non-double hit. Hum Pathol. 2025 Feb; 156:105700.
-
From the archives of MD Anderson Cancer Center: EBV-positive fibrin-associated large B-cell lymphoma in an ovarian leiomyoma with cystic degeneration: A case report and discussion of differential diagnosis. Ann Diagn Pathol. 2025 Feb; 74:152397.
-
The future of immunotherapy for diffuse large B-cell lymphoma. Int J Cancer. 2025 Jan 15; 156(2):251-261.
-
Characterization of Lymphopenia and Correlating the Risk of Cytopenias With Dose and Bone Marrow Volume Irradiated in Aggressive B Cell Lymphoma Patients Bridged With Radiation Therapy for Chimeric Antigen Receptor-T Cell Therapy. Int J Radiat Oncol Biol Phys. 2025 Mar 15; 121(4):1011-1025.
-
Evaluating the impact of laboratory-based eligibility criteria by race/ethnicity in first-line clinical trials of DLBCL. Blood Adv. 2024 08 27; 8(16):4414-4422.